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Abstract
Epithelial to mesenchymal transition (EMT) is considered an important mecha-
nism in tumor resistance to drug treatments; however, in vivo observation of
this process has been limited. In this study we demonstrated an immediate and
widespread EMT involving all surviving tumor cells following treatment of a
mouse model of colorectal liver metastases with the vascular disruptive agent
OXi4503. EMT was characterized by significant downregulation of E-cadherin,
relocation and nuclear accumulation of b-catenin as well as significant upregu-
lation of ZEB1 and vimentin. Concomitantly, significant temporal upregulation
in hypoxia and the pro-angiogenic growth factors hypoxia-inducible factor
1-alpha, hepatocyte growth factor, vascular endothelial growth factor and trans-
forming growth factor-beta were seen within the surviving tumor. The process
of EMT was transient and by 5 days after treatment tumor cell reversion to epi-
thelial morphology was evident. This reversal, termed mesenchymal to epithelial
transition (MET) is a process implicated in the development of new metastases
but has not been observed in vivo histologically. Similar EMT changes were
observed in response to other antitumor treatments including chemotherapy,
thermal ablation, and antiangiogenic treatments in our mouse colorectal metas-
tasis model and in a murine orthotopic breast cancer model after OXi4503
treatment. These results suggest that EMT may be an early mechanism adopted
by tumors in response to injury and hypoxic stress, such that inhibition of
EMT in combination with other therapies could play a significant role in future
cancer therapy.
Introduction
The majority of cancer-related deaths (90%) occur due to
uncontrolled metastasis despite the development of wide
range of systemic, regional, and local therapies. Dissemi-
nated metastases that are not amenable to surgical resec-
tion are usually treated with systemic chemotherapies.
Such treatments nonspecifically target proliferating tumor
cells, with cytotoxic effects on proliferating host cells and
are associated with the development of drug resistance [1].
Tumor targeting approaches have recently been explored
either targeting pathways and molecules that are specifi-
cally or preferentially expressed in tumors, or exploiting
the differential sensitivity of the tumor vasculature to anti-
angiogenic drugs and vascular disruptive agents (VDAs).
The clinical efficacy of these new therapies has not yet lived
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up to their experimental promise with the majority of
patients developing eventual recurrence [2]. Drugs that
specifically target existing tumor vasculature can effectively
destroy more than 90% of a solid tumor [3]. A small num-
ber of resistant tumor cells survive in the tumor periphery
after treatment and invariably result in recurrence. This
localized resistance to VDAs has been reported in many
preclinical tumor models and in clinical trials in different
types of malignancies [4]. Localized resistance is likely due
to significant heterogeneity within a solid tumor. This
arises not only from genetic mutations accumulating by
the continuous proliferation of tumor cells, but also due to
differences in the local microenvironment of individual
tumor cells [1]. In a recent study we demonstrated tumor
cells that survive treatment with the VDA OXi4503 in the
periphery have a significantly different microenvironment
to the rest of the tumor [5]. These differences included
vascular morphology, oxygen availability, cytokine and
growth factor composition, and stromal cell association. A
number of other published studies have also reported sig-
nificant tumor and stromal differences between the bulk of
the tumor and the invasive front (included in the periph-
ery of our studies) and suggest these differences contribute
to drug resistance [6] and metastasis [7, 8]. In our earlier
study we demonstrated reduced proliferation and apopto-
sis within the viable rim compared with the rest of the
tumor after vascular targeting treatment [5]. In the present
study we examined molecular and morphological changes
in the surviving tumor cells after treatment, which may
enable them to avoid apoptosis. We identified significant
temporal changes in the expression of several growth fac-
tors within the surviving tumor region, and most notably
we showed a widespread but transient EMT involving all
of the surviving tumor cells. EMT is known from in vitro
studies to confer resistance to drug treatment and is impli-
cated in the development of tumor resistance in vivo [9,
10]. We also observed similar EMT changes when other
antitumor treatments are used including chemotherapy,
thermal ablation, and antiangiogenic treatments.
Material and Methods
Animals
Six- to eight-week-old male CBA mice (Laboratory
Animal services, University of Adelaide, South Australia)
were used in all CRC liver metastases (CRCLM) experi-
ments. Five- to seven-week-old female BALB/c mice
(WEHI, Melbourne, Australia) were used for the mouse
mammary cancer experiments. Mice were maintained
in standard cages with access to irradiated food
and water ad libitum, and exposed to a twelve hour
light/dark cycle. All procedures were implemented in
accordance with the guidelines of the Austin Animal
Ethics Committee.
Experimental model of CRCLM
The primary mouse colorectal (MoCR) cancer cell line
was derived from a dimethyl hydrazine (DMH)-induced
primary colon carcinoma in the CBA mouse and main-
tained in vivo by serial passage in the flanks of CBA mice
[11]. For passage and experimentation, subcutaneous
tumors were teased apart, passed through a filter, treated
with ethylenediaminetetraacetic acid (EDTA), and washed
in phosphate buffered saline (PBS) to make a single cell
suspension. Liver metastases were induced by intrasplenic
injection of 5 9 104 tumor cells followed by splenectomy
[11]. Metastases are fully established by 21 days following
tumor induction [11].
Experimental model of mammary cancer
(4T1.2)
Amouse model of spontaneous breast cancer metastasis was
used as previously described [12]. 4T1.2 cells (kindly pro-
vided by A/Prof. Robin Anderson, Peter MacCallum Cancer
Centre, Melbourne, Australia) were routinely cultured in
DMEM (Gibco BRL, Victoria, Australia) containing 10%
fetal bovine serum (Gibco BRL, Victoria, Australia) and in a
37°C/5% CO2 humidified incubator. A 15 lL solution con-
taining 1 9 105 4T1.2 cells were inoculated bilaterally into
the mammary fat pad, then tumors grown for 14 days. Four
animals per group were used. Tumors had a 100% take rate.
Mice then received either vehicle (saline) or a single dose of
OXi4503 at day 14 as described below.
OXi4503 treatment protocol
Treatment was administered 16 days after induction of
liver metastases or 14 days after breast tumor induction
when tumors are well established. OXi4503, kindly
donated by OXiGENE (OXiGENE Inc. South San Fran-
cisco, CA), was freshly prepared by dissolving in 0.9% ster-
ile saline (NaCl) while being protected from light. A single
maximum tolerated dose of OXi4503, previously deter-
mined to be 100 mg/kg, was administered via intraperito-
neal injection [13]. Control groups were administered an
equivalent volume of sterile saline. Tissues were collected
at 1 h, 24 h, and 5 days following OXi4503 treatment.
Other treatment modalities
Tumor tissues from three other treatment modalities were
examined for evidence of EMT changes. In each case tumor
metastases were established as described above and a mini-
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mum of four animals per group were used. In the first treat-
ment mice bearing liver metastases were treated with a single
dose of the cytotoxic agent SMA-pirarubicin at 18 days post
tumor induction. The drug dose of 250 mg/kg SMA-piraru-
bicin is equivalent to 100 mg free pirarubicin and was given
intravenously via the tail vein in 0.2 mL saline solution [14].
Tissues from that study were collected at 3 days after treat-
ment and stained for EMT markers. The second treatment
investigated ablated tumor tissues from mice that had two
selected tumor metastases ablated by laser application on
day 21 post tumor induction as described previously [15].
Tissues from that study were collected at 24 h following
treatment and stained for EMT markers. The third treat-
ment investigated the effects of a single dose of sunitinib at
40 mg/kg, administered IP on day 16 post tumor induction.
Tissues from that study were collected at 24 h following
treatment and stained for EMTmarkers.
Definition of tumor periphery
Tumor periphery in our studies consisted of the area
encompassing the tumor–host interface and extending one
hundred microns toward the tumor center. All the remain-
ing tumor area was considered part of the tumor center.
Detection of tumor hypoxia
Pimonidazole was used as a marker of tumor hypoxia.
Pimonidazole hydrochloride was dissolved into 0.9%
NaCl and administered intravenously to tumor-bearing
mice in doses of 30 mg/kg. The livers were removed 1 h
after pimonidazole administration and fixed in 10% for-
malin in 0.1 mol/L phosphate buffer, pH 7.2. Hypoxic
tumor regions were detected immunohistochemically by
established techniques [16].
Assessment of epithelial to mesenchymal
transition
The main indicators of epithelial to mesenchymal transi-
tion (EMT) are downregulation of E-cadherin (cell junc-
tion protein), nuclear accumulation of b-catenin (cell
junction protein), upregulation of the mesenchymal mar-
ker vimentin, and upregulation of transcriptional drivers of
EMT such as ZEB1 [17, 18]. Changes in these markers were
assessed using immunohistochemistry and immunoblot.
Immunohistochemistry
Table S1 presents a list of antibody concentrations and assay
conditions used. Formalin-fixed paraffin tissue sections
(4 lm) were used with an indirect peroxidase labeling tech-
nique (Envision Plus, DAKO, Campbellfield, Australia).
Following deparaffinization and rehydration, endogenous
peroxidase activity was blocked with 3% H2O2 and nonspe-
cific binding inhibited with 10% normal goat serum (01-
6201 Zymed Laboratories, San Francisco, CA). Epitope
retrieval was conducted as per Table S1. Sections were incu-
bated with primary antibodies or the respective nonimmune
antibody isotypes overnight at 4°C. Sections treated with
the rat antibodies were subsequently treated with a rabbit
anti-rat IgG linker antibody before treatment with a poly-
mer-based detection kit containing goat anti-rabbit immu-
noglobulins (IgG) linked to horseradish peroxidase (HRP)
(Envision Plus, Dako). Each incubation step was followed
by 2- to 5- min washes with PBS + 0.05% Tween 20. Posi-
tive staining was visualized using diaminobenzidine (DAB)
as a substrate. Between 75 and 120 tumors were assessed for
each time point/treatment group. Each group consisted of a
minimum of five animals and up to a maximum of 10. Each
animal had several liver metastases (discrete tumors) of var-
ious sizes. Liver sections were taken to include the entire
liver in the analysis and each section contained from one to
several tumors. Individual tumors were often represented in
more than one sections. Images of stained tumors were cap-
tured using a digital light microscope (Nikon Coolscope,
Nikon Corporation, Japan) at between 109 and 4009 mag-
nification. The images of tumor fields were captured to be
representative of the entire tumor periphery, using a raster
pattern which allowed for fields captured to be random and
not overlap [19]. Between 10 and 30 fields per tumor were
assessed. The images were analyzed using Image-Pro plus
(Version 5, Media Cybernetics, Perth Australia). Only areas
of viable tumor were considered in the analysis. Changes in
hypoxia and the antigens AT1R, vascular endothelial growth
factor (VEGF), hypoxia-inducible factor 1-alpha (HIF-1a),
E-cadherin, Vimentin, b-catenin, and ZEB1 were assessed
by microscopy and representative images are presented.
Changes in expression wherever possible were evaluated
using a semi-quantitative scoring system. Areas of interest
were identified using a light microscope (Olympus BH2,
Tokyo, Japan) at a magnification of 1259. Scoring criteria
was used to estimate the amount and intensity of staining
seen in each sample. The grading system used was as fol-
lows: 0: no staining 1: faint staining; 2: small amount or
weak staining; 3: moderate staining; 4: abundant or strong
staining; 5: Abundant or very strong staining. Means for
each group were determined using the individual average
scores from each animal in the group. Scoring researchers
were blinded in regard to the experimental group.
Preparation of liver and tumor tissue
lysates
Collected tissues from control and treated animals were
snap-frozen in liquid nitrogen to be used for protein
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preparations. Each sample contained several individual
tumor metastases from the same animal or several liver
sections from different areas of the liver for each animal.
The frozen tissues were weighed into microcentrifuge
tubes and kept on ice. Cold lysis buffer (50 mmol/L
hydroxyethyl piperazineethanesulfonic acid (HEPES),
150 mmol/L NaCl, 10 mmol/L EDTA, 10 mmol/L
Na4P2O7, 10 mmol/L NaF, 2 mmol/L Na3VO4, 0.5 mmol/
L phenylmethylsulfonyl fluoride, 20 lmol/L Leupeptine,
10 lg/mL Aprotinin, and 1% Triton X-100) was added to
each tissue at a ratio of 500 lL/mg tissue weight. The tis-
sues were homogenized using an Ultra Turrax T25 ho-
mogeniser (John Morris Scientific Pty Ltd., Sydney,
Australia) in three ten second bursts while the sample
was kept on ice. The homogenates were then sonicated
with three 10 second bursts using a Branson Sonifier 250
(Branson Ulrasonics Co., Danbury, CT) at 30 Hz constant
output, while the sample was kept on ice. The sonicates
were centrifuged at 17,000 g at 4°C for 15 min and the
supernatant (lysate) was collected, aliquoted, and kept
frozen at 80°C until used. Protein concentrations were
determined by the Bradford reagent (Sigma).
Immunoblot
Pooled tumor lysates representing equal amounts of
protein from each animal in the group (n = 4 per group)
were resolved by sodium dodecyl sulfate polyacrylamide
gel electrophoresis and proteins were detected with anti-
bodies against E-cadherin and GAPDH (Genesearch, Mel-
bourne, Australia). The bound antibodies were visualized
using ECL reagents (GE Healthcare, Buckinghamshire,
U.K.). Relative changes in E-cadherin concentration was
determined by normalization using GAPDH as internal
standard.
Enzyme linked immuno sorbent assay
The levels of the growth factors VEGF, hepatocyte growth
factor (HGF), and TGF-b1 in tissue extracts were deter-
mined by a sandwich enzyme linked immuno sorbent
assay (ELISA) using commercially available kits (mouse
Duosets, VEGF Cat No: DY493 and TGF-b1 DY1679,
R&D Systems, Minneapolis MN) according to the manu-
facturer’s instructions with minor modifications. In brief
96-well microplates (Nunc Immuno Plate maxisorb, In
Vitro Technologies, Victoria, Australia) were coated with
50 lL per well of suitably diluted capture antibody and
incubated overnight at 4°C. Following blocking with
reagent diluent, the test samples and standards were
applied at appropriate concentrations. Transforming
growth factor-beta (TGF-b) samples were activated using
2.5 N Acetic Acid/10 mol/L and neutralized by 2.7 N
NaOH/1.0 mol/L HEPES before being applied onto the
ELISA plate. After 2 h incubation, the biotinylated detec-
tion antibody was added followed by Streptavidin-HRP.
The plate was washed before each successive step with
0.05% Tween 20 in PBS. Substrate (H2O2 and Tetrameth-
ylbenzidine, R&D Systems Catalog number DY994) was
added and developed for 20 min at room temperature,
followed by the addition of 25 lL of stop solution (2N
H2SO4). The optical density was determined immediately
using a BioRad microplate reader (Benchmark Plus
Microplate Spectrophotometer System, Bio-Rad Laborato-
ries, Hercules, CA) set at dual wavelengths of 450 and
540 nm. The 540 nm reading was subtracted from the
450 nm reading. Using a computer generated four param-
eter logistic curve fit from the standard concentrations
(4-PL), the unknown sample concentrations were directly
calculated by the spectrophotometer software.
Statistical analysis
Quantitative data are represented as the mean  standard
error of the mean. Statistical analysis was conducted using
SPSS (Statistical Package for the Social Sciences,TM version
10, Chicago, IL) with normality testing and use of both
parametric and nonparametric analytical tests as appropri-
ate. All statistical tests were two sided and a P-value of 0.05
or less was considered statistically significant.
Results
Histological changes following Oxi4503
treatment
One hour after Oxi4503 treatment, widespread apoptosis
and necrosis occurred in the center of the tumor due to
vessel occlusion. This can be seen by the fragmenting and
pyknotic cell nuclei staining indicating apoptosis and
often total absence of nuclear staining indicating necrosis
in hematoxylin and eosin (H&E) staining (Fig. 1, 1 h
treated). Apoptosis was also evident by extensive caspase
3 staining (Fig. S1, 1 h treated). Intact viable tumor was
present only in a thin rim at the tumor periphery as can
be seen by their normal nuclear morphology. (Fig. 1, 1 h
treated). Even within the viable rim several tumor cells
were caspase positive indicating that not all tumor cells in
this area survive (Fig. S1, 1 h treated). Twenty-four hours
after treatment tumor cells in the viable tumor rim
appeared disorganized and less dense than in the control
or at 1 h time point (Fig. 1, 24 h treated); however, also
fewer cells were caspase positive (Fig. S1, 24 h treated).
By day five tumor growth had resumed with tumor cells
growing into the necrotic center. The majority of tumor
cells were organized into nodules; however, there were
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many single tumor cells not organized (Fig. 1, 5 day trea-
ted, third panel, double arrows), and large infiltration of
host cells were seen into the tumor especially in the
tumor–host interface (Fig. 1, 5 day treated, middle
panel). Some apoptotic cells were seen among the new
tumor growth mainly confined toward the necrotic center
(Fig. S1, 5 day treated).
OXi4503 treatment induces acute hypoxia
and upregulation of pro-angiogenic growth
factors in the surviving viable tumor
In control animals tumor tissue at the tumor–host inter-
face was normoxic (Fig. 2, control, arrows) while intense
hypoxia is seen in central parts of the tumor especially
those distant from blood vessels. Following treatment the
viable tumor rim displayed acute increase in hypoxia
compared with untreated control (Fig. 2, 1 h treated,
arrows). The same pattern is seen at 24 h after treatment
(Fig. 2, 24 h treated). Five days after treatment the viable
rim had regrown significantly and the hypoxia pattern
resembled that of the untreated control and was mainly
seen within regions distant from vasculature and close to
necrotic areas (Fig. 2, 5 day treated). Levels of HIF-1a,
known to be stabilized by hypoxia, were also investigated.
In untreated tumor HIF-1a was expressed at low levels in
the cytoplasm and nucleus of most tumor cells but was
strongly expressed in the nucleus of a proportion of cells
interspersed throughout the tumor (Fig. 3, control
arrows). Following OXi4503 treatment there was an
increase in HIF-1a staining in the cytoplasm and nucleus
of almost all the surviving tumor cells (Fig. 3, 1 h and
24 h treated). HIF-1a levels remained high mainly in the
tumor cytoplasm at day five despite reduction in hypoxia
staining (Fig. 3, 5 day treated). A proportion of tumor
cells displayed nuclear HIF-1a expression (Fig. 3, 5 day
treated double arrows) and many HIF-1a positive infil-
trating cells were seen in the tumor periphery (Fig. 3,
5 day treated, arrowheads).
In a previous study, we found upregulated expression
of VEGF, ATR1, and TGF-b preferentially associated with
the tumor periphery [5]. In the current study we found
Figure 1. Hematoxylin and eosin staining of CRCLM tumors following OXi4503 treatment. Mice with liver metastases were treated with a single
IP dose of OXi4503 (100 mg/kg) at 16 days post tumor induction. Tissues were collected at indicated times following OXi4503 treatment. First
column, black bar = 250 lm, second column, black bar = 50 lm, third column = magnified inset of second column. L, liver; T, tumor; N,
treatment induced necrosis. Double black lines in the second and third panels first column outline the viable tumor rim at 1 and 24 h
posttreatment. Single red arrows in second and third panels of columns 2 and 3 indicate the viable tumor rim and arrowheads indicate apoptotic
cells. Double arrows in the 5 day treated magnified inset indicate single tumor cells not yet organized into nodules.
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VEGF and ATR1 expressed mainly in the nucleus and
cytoplasm of infiltrating cells and in the cytoplasm of
some tumor cells in the periphery (Fig. 4A, control and
Fig. S2, contol). Following OXi4503 treatment VEGF
staining was further upregulated within the viable tumor
and was mainly located in the tumor cytoplasm and the
cytoplasm and nucleus of infiltrating cells (Fig. 4A, VEGF
1 h and 24 h treated and Fig. S2). VEGF staining
returned to control levels by day five in the regrowing
tumor (Fig. 4A, VEGF, 5 day treated and Fig. S2, VEGF
5 day treated). Similarly AT1R staining increased at 1 h
after treatment but by day five it had returned to baseline
levels (Fig. 4A and S2).
Temporal local and systemic changes in HGF, TGF-b,
and VEGF in response to OXi4503 treatment were also
evaluated by ELISA assays. Following treatment the con-
centration of HGF and VEGF significantly increased in
the tumor lysates at 24 h and returned to base levels by
day 5 (Fig. 4B) confirming our immunohistochemistry
results for VEGF. In contrast TGF-b increased signifi-
cantly only at day 5 (Fig. 4B). In addition, there was
parenchymal and systemic modulation of these growth
factors. VEGF levels increased significantly at 24 h in the
serum and showed an increasing trend in the liver paren-
chyma (Fig. S3, column 3). In contrast HGF and TGF-b
levels decreased in the serum following treatment; HGF
showed significant decrease at 5 days and TGF-b at 24 h
and 5 days (Fig. S3, row 2). HGF levels did not change in
liver lysates while TGF-b significantly decreased at 24 h
(Fig. S3). These results demonstrate that OXi4503
treatment exerts differential effects on local and systemic
cytokine and growth factor concentration, and this modu-
lation may contribute to tumor resistance.
OXi 4503 treatment induces changes in EMT
markers in the surviving viable tumor
The temporal increase in angiogenic growth factors led us
to investigate changes in EMT markers as many studies
suggested that growth factors including HIF-1a, TGF-b,
VEGF, and HGF are responsible for EMT changes giving
rise to invasive and metastatic tumors [20–22]. Down-
regulation of E-cadherin is regarded as the hallmark of
EMT so we initially investigated changes in E-cadherin fol-
lowing treatment. We determined that E-cadherin was
highly expressed in the untreated control tumors giving
the characteristic cobblestone appearance (Fig. 5A, control
and Fig. S4, control). Surprisingly, within 1 h of treatment,
Figure 2. Changes in hypoxia in CRCLM tumors following OXi4503 treatment. Mice with liver metastases were treated with a single IP dose of
OXi4503 (100 mg/kg) at 16 days post tumor induction. Tissues were collected at indicated times following OXi4503 treatment. Hypoxia was
detected by Pimonidazole staining (brown staining indicating positive for hypoxia). First column, black bar = 250 lm, second column black
bar = 50 lm, third column = magnified inset of second column. L, liver; T, tumor; N, treatment induced necrosis. Double arrows indicate tumor
at the tumor–host interface in the control and the regenerating tumor at 5 days after treatment showing minimal hypoxia. Single red arrows in
all panels of second and third row indicate tumor cells within the viable rim at 1 and 24 h staining strongly for hypoxia.
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E-cadherin was dramatically downregulated within the
entire viable tumor rim (Fig. 5A, 1 h treated and Fig. S4,
1 h treated). This downregulation persisted for 24 h
posttreatment (Fig. 5A, 24 h treated and Fig. S4, 24 h trea-
ted). At this time point the tumor cell boundaries
appeared disorganized and the cells had adopted a less
rounded morphology. While E-cadherin staining increased
again by day five, overall it was significantly lower than the
control (Fig. 5A, 5 day treated and Fig. S4, 5 day treated).
At day five the majority of tumor cells appeared organized
in clusters but also several detached tumor cells were clearly
visible (Fig. 5A, 5 day treated, inset arrowheads). Quantifi-
cation of the E-cadherin changes showed significant differ-
ences between controls and OXi4503 treated groups at all
three time points after treatment (Fig. 5B). E-cadherin
changes were also confirmed using Western blotting of
tumor lysates (Fig. 5C and D). The results clearly demon-
strate decreased E-cadherin concentration following treat-
ment, thus verifying the immunohistochemistry results.
We next investigated changes in b-catenin as this pro-
tein combines with E-cadherin to stabilize the cell junc-
tions. In the control tumors b-catenin displayed similar
distribution to E-cadherin; staining localized at the
cell junctions giving a cobblestone appearance (Fig. 6A,
b-catenin control and Fig. S4). Within 1 h following
treatment, redistribution of b-catenin was seen away from
the adherens junctions and accumulation in the cyto-
plasm and nucleus (Fig. 6A, b-catenin 1 h treated
and Fig. S4). Cytoplasmic and nuclear localization of b-
catenin persisted at the next two time points and the
nuclear accumulation became more intense at day five
(Fig. 6A, b-catenin 5 day treated and Fig. S4). Changes in
the ZEB1 transcription factor an E-cadherin repressor
were also investigated. ZEB1 was found to be expressed in
the untreated control tumors by infiltrating cells that
accumulate at the tumor–host interface and along major
vessels (Fig. 6B, ZEB1 control and Fig. S4). Based on
their morphological appearance, these cells closely resem-
ble fibroblasts (Fig. 6B, ZEB1 control, inset arrowheads).
The occasional tumor cell also displayed positive staining.
Following OXi4503 treatment at 1 h there was nuclear
staining in the majority of viable cells in the tumor rim
(Fig. 4B, ZEB1 1 h treated and Fig. S4). The staining
increased and became predominantly cytoplasmic at 24 h
after treatment. All surviving tumor cells expressed cyto-
plasmic ZEB1 at this time point (Fig. 6B, ZEB1 24 h trea-
ted). By day 5 posttreatment, however, only weak ZEB1
staining remained in the tumor cytoplasm and the stain-
Figure 3. Changes in HIF 1a expression levels in CRCLM tumors following OXi4503 treatment. Mice with liver metastases were treated with a
single IP dose of OXi4503 (100 mg/kg) at 16 days post tumor induction. Tissues were collected at indicated times following OXi4503 treatment.
Expression of HIF 1a (brown staining) was detected using anti-HIF 1a antibodies. First column, black bar = 200 lm, second column black
bar = 50 lm, third column = magnified inset of second column. L, liver; T, tumor; N, treatment induced necrosis. Double arrows indicate
occasional tumor cells showing strong nuclear staining. Single red arrows in all panels of second and third row indicate that tumor cells within the
viable rim at 1 and 24 h show strong cytoplasmic and nuclear staining for HIF 1a. Arrowheads indicate infiltrating cells with strong HIF 1a staining.
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ing pattern resembled the control with only infiltrating
stroma cells displaying strong nuclear staining (Fig. 6B,
ZEB1 5 day treated and Fig. S4).
Changes in vimentin staining were also examined. In the
untreated control tumor there was low expression of
vimentin protein (Fig. 6C, vimentin control and Fig. S4).
Within an hour of treatment strong upregulation of vimen-
tin staining was seen within the viable tumor rim with both
cytoplasmic and nuclear localization clearly prominent
(Fig. 6C, vimentin 1 h treated). The vimentin upregulation
persisted at the next two time points with levels signifi-
cantly higher than the control (Fig. 6C, vimentin 24 h and
5 day treated and Fig. S4). At day 5, the staining intensity
of vimentin was stronger in the tumor cells repopulating
the necrotic center of the tumor and weaker toward the
tumor–host interface (Fig. 6C vimentin 5 day treated). The
changes in staining were quantified for ZEB1 and vimentin
expression and as indicated in the graphs (Fig. 6D and E)
they were significantly higher compared with untreated
controls at 24 h and 5 day time points, respectively. Taken
together the results demonstrate that OXi4503 treatment
induces very rapid and widespread EMT involving practi-
cally all surviving tumor cells. Furthermore, the EMT
changes were transient; by day five following treatment the
regrowing tumor appeared to be undergoing a mesenchy-
mal to epithelial transition (MET) in the process of revert-
(A)
(B)
Figure 4. Temporal changes in proangiogenic growth factor/receptor levels in tumors following OXi4503 treatment. Mice with liver metastases
were treated with a single IP dose of OXi4503 (100 mg/kg) at 16 days post tumor induction. (A) Temporal changes in VEGF and AT1R expression
following OXi4503 treatment determined by immunohistochemistry. Tissues were collected at indicated times following OXi4503 treatment.
Expression (brown staining) was detected using the appropriate antibodies. Black bar = 50 lm, second column and fourth column
panels = magnified inset of second column and third column panels. L, liver; T, tumor; N, treatment induced necrosis. Double arrows indicate
occasional tumor cells showing strong nuclear staining. Single red arrows in all panels of second and third row indicate that tumor cells within
the viable rim at 1 and 24 h show increased VEGF and AT1R staining. Black arrows in second and fourth panels in the control tumors indicate
infiltrating cells expressing VEGF and AT1R. (B) Temporal changes in VEGF, HGF, and TGF-b determined by ELISA. Tumor tissues were collected at
indicated times following OXi4503 treatment. Growth factor concentration was determined in tumor lysates by capture ELISA assays using
commercially available kits (R&D Duo Kits) , control tumor bearing mice; , Oxi4503-treated tumor-bearing mice. The data are mean
values  SEM (n = 10) VEGF, OXi4503 treated at 24 h *P < 0.05 compared with untreated control, HGF, OXi4503 treated at 24 h *P < 0.0009
compared with untreated control. TGF-b, OXi4503 treated at 5 days following *P < 0.0009 compared with untreated control.
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ing to epithelial morphology as judged by the nodule
arrangement, E-cadherin association with the adherens
junctions and the ZEB1 downregulation. The process, how-
ever, was not totally completed as the predominant nuclear
expression of b-catenin and the persistent high levels of
vimentin suggest.
Chemotherapy and other treatment
modalities of liver metastases induce EMT
in residual tumor
Based on the findings with OXi4503 treatment in this
study we hypothesized that similar morphological changes
occur in other tumor treatments, we therefore examined
archival tumor tissues from previous studies for evidence
of EMT induction. In a previous study we reported signifi-
cant tumor damage and acute hypoxia within residual
tumors after treatment with the cytotoxic agent SMA-
pirarubicin [14]. Tissues from that study, collected at
3 days after a single SMA-pirarubicin treatment, were
stained for EMT markers. The results showed a large
decrease in E-cadherin staining and a reciprocal strong
increase in the staining of ZEB1 and vimentin compared
with control tumor (Fig. 7, control and SMA-pirarubicin
treated). The second treatment examined was an earlier
study of tumor thermal ablation by laser application. This
is a localized treatment of individual tumors and results in
extensive immediate tumor necrosis at the ablation site
[15]. Staining of tissues collected 24 h after treatment
displayed extensive decrease in E-cadherin and increase in
ZEB1 and vimentin in surviving tumor adjacent to the
thermal injury compared with control (Fig. 7, control and
thermal ablation treated). The third treatment we investi-
gated was the antiangiogenic agent sunitinib. This agent is
used to inhibit the formation of new blood vessels and it is
also known to induce the regression of microcapillaries. It
is normally administered continuously, but we examined
EMT changes at 24 h after a single dose. In our model this
(A)
(B) (C)
(D)
Figure 5. Reduction in E-cadherin following OXi4503 treatment. Mice with liver metastases were treated with a single IP dose of OXi4503
(100 mg/kg) at 16 days post tumor induction. Tissues were collected at 1, 24 h, and 5 days following Oxi4503 treatment. (A) Formalin-fixed
tumor sections were stained with antibodies to E-cadherin. Positive expression is detected by the brown staining. L, liver; T, tumor; N, treatment
induced necrosis. Red arrows indicate area of the viable tumor rim; Arrowheads indicate unattached tumor cells that do not express E-cadherin.
Black bar = 50 lm. Panels in columns two and four represent magnification of corresponding insets in columns one and three. (B) Quantification
of E-cadherin using an intensity scoring system. Untreated control versus OXi4503 treated at all time points, *P < 0.001. (C) Western blot of
pooled tumor lysates (n = 4 per group) stained for E-cadherin, Lanes: (1) 1 h control; (2) 1 h Oxi4503 treated; (3) 24 h control; (4) 24 h Oxi4503
treated. (D) Normalization of E-cadherin concentration using GAPDH as internal standard.
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treatment results in central tumor necrosis with viable
tumor persisting in the outer tumor regions (Fig. 7, suniti-
nib treated). Staining for EMT markers revealed a decrease
in E-cadherin especially in areas adjacent to necrotic
regions and increase in ZEB1 and vimentin compared with
control tumor (Fig. 7, control and sunitinib treated). The
sunitinib single treatment is a milder treatment compared
with OXi4503 as judged by the surviving tumor mass and
interestingly while vimentin and ZEB1 are upregulated
throughout the remaining live tumor, E-cadherin is only
downregulated near the necrotic areas resulting from the
treatment (Fig. 7, control and sunitinib treated). Taken
together these results indicate that EMT is a general pro-
tective mechanism adopted by MoCR tumors in response
to treatment stress.
OXi4503 treatment induces EMT changes in
a murine breast cancer model
Epithelial to mesenchymal transition markers were also
investigated in a murine breast cancer model produced by
injection of a murine breast cancer cell line into the mam-
mary fat pads of syngeneic mice. This cell line has more
mesenchymal characteristics – E-cadherin is expressed at
low levels and the characteristic cobblestone appearance of
solid epithelial tumors is less evident. ZEB1 is expressed by
infiltrating cells and some tumor cells and vimentin is also
expressed at low levels (Fig. 8, control). OXi4503 treatment
was administered as for the colorectal liver metastasis
model without further optimization. At the dose tested, the
treatment resulted in extensive tumor damage with only
small patches of intact tumor surviving at the tumor
periphery adjacent to host fat tissue. There was not a con-
tinuous rim of live tumor as seen in the CRCLM tumors
indicating that this particular tumor is very sensitive to
OXi4503. EMT changes further increased the mesenchymal
characteristics of this tumor as discerned by the decrease in
E-cadherin and the increase in ZEB1 and vimentin (Fig. 8).
Overall these results suggest that EMT may be broadly
adopted by tumors under stress to escape apoptosis.
Discussion
Tumor treatment with VDA results in extensive tumor
killing but leaves a characteristic rim of live tumor in the
periphery which results in tumor recurrence [3, 4]. In an
(A) (B) (C)
(D) (E)
Figure 6. Changes in EMT markers following OXi4503 treatment of tumor metastases. Mice with liver metastases were treated with a single IP
dose of OXi4503 (100 mg/kg) at 16 days post tumor induction. Tissues were collected at 1, 24 h, and 5 days following OXi4503 treatment.
Formalin-fixed control and treated tumor sections were stained with (A) antibodies to b-catenin, (B) antibodies to ZEB1, and (C) antibodies to
vimentin. Positive expression is detected by the brown staining. Red arrows indicate area of the viable tumor rim; arrowheads in B control panel
indicate host infiltrating cells staining strongly positive for ZEB1. Black bar = 50 lm. Panels in second column of A–C depict respective magnified
insets. (D and E) Quantification of ZEB1 and vimentin, respectively, using an intensity scoring system. *P < 0.05, **P < 0.015.
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earlier study we demonstrated significant molecular and
morphological differences between the tumor periphery
and the rest of the tumor that could account for the
tumor resistance to VDAs in this region [5]. In the pres-
ent study we investigated tumor and host responses, fol-
lowing OXi4503 treatment, which may further contribute
to tumor survival. We demonstrated immediate increases
in hypoxia and HIF-1a levels. Hypoxia stabilizes the
HIF-1a protein resulting in the activation of over 100
genes. Many of these genes support angiogenesis while
others are responsible for the modification of extracellular
matrix, the influx of supportive cells, cytoprotection, tol-
erance to low oxygen levels, or promote EMT [23]. We
also demonstrated temporal local and systemic changes in
growth factors (HGF, VEGF, and TGF-b) that are also
known to be pro-angiogenic and support tumor growth
[24]. Some of these growth factors were shown in other
studies to be induced by hypoxia and HIF-1a [20, 23].
HGF and VEGF increased significantly within 24 h of
treatment. Both of these factors, in addition to their
angiogenic contribution, have been shown in other set-
tings to be cytoprotective in tissue injury and cytotoxic
drug treatments [25]. TGF-b did not increase significantly
within the tumor until day five. Increases in growth
factors and cytokines (VEGF, granulocyte-colony stimu-
lating factor and stromal cell-derived factor 1) were also
reported following VDA treatment in other tumor models
and were shown to induce mobilization of bone marrow-
derived cells, including circulating endothelial progenitor
cells that colonize the viable tumor rim and contribute to
tumor regrowth [6, 26]. Collectively our results and the
published data demonstrate that a robust pro-angiogenic
response is induced by VDA treatment that contributes to
tumor regrowth. In addition, to pro-angiogenic contribu-
tion these growth factors (HIF-1a, HGF, VEGF, and
TGF-b) are known to induce and sustain EMT in tumors
[21, 27, 28] conferring invasiveness and resistance to drug
treatments [22, 29].
The most striking finding of our study was the immedi-
ate and widespread EMT in virtually all surviving tumor
cells in the periphery. The speed and the extent of this
transition were totally unexpected. Although EMT has
been implicated as a major mechanism for the develop-
ment of drug resistance [9], findings similar to ours have
not been demonstrated previously. This may be related to
the majority of published studies being conducted in vitro.
In cell culture EMT induction in response to drug treat-
ment or to growth factor stimulation occurs over a much
longer period ranging from a few days to several weeks
[27, 30]. In addition, it has also not been seen in clinical
samples as these tumor samples are not collected immedi-
ately after treatment. Recent publications reported
increased mesenchymal morphology in recurrent tumors
following longer treatment regimens. One such study
reported that residual breast tumor biopsies exhibited both
stem cell and mesenchymal features after neoadjuvant
Figure 7. Changes in EMT markers following different treatment of
CRLM tumor metastases. Formalin-fixed control and treated tumor
sections were stained with antibodies to E-cadherin, vimentin, and
ZEB1. Positive expression is detected by the brown staining. L, liver; T,
tumor; N, necrosis resulting from treatment; LT, live tumor remaining
after treatment. Low magnification scale bar = 250 lm, high
magnification scale bar = 50 lm. Control tissues were collected on
day 21 post tumor induction. For the SMA-pirarubicin treatment mice
with liver metastases were treated with a single IP dose of SMA-
pirarubicin at 18 days post tumor induction [14]. Tissues were
collected 3 days following treatment. For thermal ablation mice with
liver metastases had two selected tumors thermally ablated using laser
treatment on day 21 post tumor induction. Tissues were collected
24 h after treatment [15]. For the sunitinib treatment mice with liver
metastases were treated with a single IP dose of sunitinib at 16 days
post tumor induction. Tissues were collected 24 h after treatment.
Arrows in the high magnification panel of sunitinib treatment indicate
reduction in E-cadherin in tumor cells adjacent to necrotic areas.
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hormone or chemotherapy treatment [10]. Another study
used oxaliplatin treatment on an orthotopic nude mouse
model of human hepatocellular carcinoma, and demon-
strated significantly increased metastasis and molecular
changes consistent with EMT [31]. In both these studies
tumor tissues were examined several days after completion
of treatment. By this time tumors that were not completely
destroyed are likely to have reestablished, and as shown in
our studies, the majority of cells may have reverted to an
epithelial state. Our study provides compelling histological
evidence of EMT occurring following in vivo treatment.
Within 1 h of treatment dramatic changes in four key
EMT markers were observed; E-cadherin levels decreased
dramatically, b-catenin was redistributed to cytoplasm and
nucleus, while ZEB1 and vimentin levels increased dramat-
ically. Nuclear localization of b-catenin indicates the acti-
vation of b-catenin-dependent Wnt signaling and the
b-catenin/TCF transcriptional target genes that are associ-
ated with tumor invasion and metastasis [32]. An inverse
correlation between ZEB1 and E-cadherin has been
reported in clinical and experimental studies and this rela-
tionship is a prognostic indicator of poor survival and
resistance to several drugs [9]. ZEB1 has also been shown
to downregulate several other polarity proteins [33]. Clar-
haut et al. [34] demonstrated that silencing of ZEB1
resulted in upregulation of E-cadherin and increased drug
sensitivity. ZEB1 has been associated with aggressive behav-
ior of colorectal tumors and uterine cancers. In another
study, upregulation of ZEB1 and the loss of E-Cadherin
correlate with resistance to gefitinib (an epidermal growth
factor receptor inhibitor), and with a poor prognosis [35].
The most likely reason for the widespread EMT
observed immediately following treatment is to protect
the cells at the injury site by two mechanisms: by prevent-
ing proliferation and inhibiting apoptosis. Our previous
findings demonstrated that both of these pathways were
significantly impacted in the first 24 h of OXi4503 treat-
ment within the remaining viable rim [5] and support
this hypothesis. Furthermore it has been postulated that
EMT enables tumors to escape from apoptosis and senes-
cence signals by adopting embryonic signaling pathways
[36, 37]. Temporal changes in ZEB1 levels, that very clo-
sely reflect our findings were reported by Bui et al. [38]
in a hypoxia-induced stroke injury model. In that study
ZEB1 was shown to induce a pro-survival response by the
transcriptional repression of pro-apoptotic factors and
upregulation of pro-survival factors. The reduced apopto-
sis seen after Oxi4503 treatment in our earlier study may
be due to a similar pro-survival function of ZEB1.
The very rapid onset of EMT following treatment
suggests posttranscriptional regulation. It is well estab-
lished that HIF-1α is stabilized by hypoxia at the protein
level [39]. The protein levels of vimentin and ZEB1 in
our study also increased far too quickly to be solely
attributed to transcriptional upregulation initially. Recent
studies have shown that regulation of protein expression
also occurs at the translational level where key driver
mRNAs are present but prevented from being translated
by either miRNAs or inhibitory proteins [40]. This type
of regulation is very important as it enables the cell to
respond very fast to environmental changes and to
produce key factors without the need for transcription.
Figure 8. Changes in EMT markers following OXi4503 treatment in orthograft of murine breast cancer. Mice with 4T1.2 breast tumors were
treated with a single IP dose of OXi4503 at 14 days post tumor induction. Tissues were collected 24 h following treatment. Formalin-fixed control
and treated tumor sections were stained with antibodies to E-cadherin, vimentin, and ZEB1. Positive expression is detected by the brown staining.
T, tumor; NT, necrotic tumor resulting from treatment; FT, fatty tissue. Arrows in the treated group indicate live tumor remaining after treatment.
Low magnification scale bar = 250 lm, high magnification scale bar bar = 50 lm.
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The rapid decrease in E-cadherin within the residual
tumor is most likely the result of proteolysis rather than
transcriptional inhibition. The increased ZEB1 levels also
ensure transcriptional inhibition of E-cadherin further
stabilizing the mesenchymal morphology of the residual
tumor. ZEB1 is known to be regulated by a double nega-
tive feed forward loop involving the miRNA 200 family
[30, 41]. In ZEB1 the translational regulation may be
achieved through association with miRNAs or other
inhibitors preventing ribosomal binding of the ZEB1
mRNA. Vimentin, the other protein which also increased
immediately following treatment, is a mesenchymal fila-
ment protein and is thought to have important functions
in morphological reorganization of cells and cell motility
hence may be associated with metastasis [42].
EMT is a complex process and the mechanisms leading
to its induction are not clear. In cell cultures EMT is usu-
ally induced by growth factors including HGF, VEGF, and
most commonly TGF-b, which is widely considered to be
the upstream driver of EMT [21]. In our study these
growth factors took several hours after treatment to upre-
gulate while TGF-b did not increase significantly until day
five. By that time the EMT process was already reversing
in the majority of tumor cells. HIF-1α and other tran-
scription factors that upregulate immediately after treat-
ment, as well as other proteins regulated at the
translational level due to ensued hypoxia and injury, are
likely to be responsible for the early EMT in drug treat-
ment. However, TGF-b may be responsible for maintain-
ing EMT morphology on an increasing fraction of tumor
cells that disseminate and give rise to metastasis [21].
Tumor cells with mesenchymal morphology, in addition
to being drug resistant, are known to be motile and inva-
sive [9]. They are believed to give rise to metastasis by
reverting to epithelial morphology through MET at distant
metastatic sites [43]. While MET is implicated in the
development of new metastases it has not been readily
observed histologically in vivo. Two recent publications
demonstrated that mesenchymal tumors induced by ecto-
pic expression of EMT inducing transcription factors
could only establish metastases if the expression of these
transcription factors was reversed [44, 45]. Our findings
indicate that the majority of surviving cells are in the pro-
cess of reverting to epithelial morphology at the site of the
original tumor within 5 days posttreatment while they still
retain significant mesenchymal features.
We also demonstrated robust EMT in response to other
treatment modalities in the mouse CRCLM model, and in
an orthotopic mouse breast tumor model. Collectively
these results suggest that fast and widespread EMT is most
likely a general response to hypoxic stress and tissue injury.
In conclusion our study suggests a central role of EMT
in therapeutic failures and the likely involvement of
translational regulation in drug induced EMT in vivo. In
vitro studies may not dependably reflect in vivo changes in
response to treatment because in vivo many factors con-
tribute through autocrine and paracrine pathways to
determine the final outcome. We identified a timeframe in
therapy treatment that should be used to unravel impor-
tant EMT mechanisms contributing to resistance and
metastasis. The observation that all surviving tumor cells
undergo EMT holds the promise that the recently
described drugs which target cells with EMT/stem cell
morphology such as salinomycin [46] in combination with
VDAs or other treatments including antiangiogenic agents
may lead to more effective therapies.
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Additional Supporting Information may be found in the
online version of this article:
Figure S1. Changes in caspase 3 staining of CRCLM
tumors following OXi4503 treatment. Mice with liver
metastases were treated with a single IP dose of OXi4503
(100 mg/kg) at 16 days post tumor induction. Tissues
were collected at indicated times following OXi4503 treat-
ment. First column, black bar = 250 lm, second column,
black bar = 50 lm, third column = magnified inset of
second column. L, liver; T, tumor; N, treatment induced
necrosis. Double black lines in second column panels out-
line the live tumor rim after treatment. Red arrows in
second and third panels of the second column indicate
the viable tumor rim at 1 and 24 h after treatment. Posi-
tive caspase 3 staining (brown staining) indicating apop-
totic cells or cell fragments. Double arrows in insets
(column 3) indicate apoptotic cells in the necrotic area
and within the viable tumor.
Figure S2. Temporal changes in VEGF and AT1R expres-
sion following OXi4503 treatment determined by immu-
nohistochemistry. Tissues were collected at indicated
times following OXi4503 treatment. Expression (brown
staining) was detected using the appropriate antibodies.
Black bar = 200 lm; L, liver; T, tumor; N, treatment
induced necrosis. Single red arrows indicate that tumor
cells within the viable rim at 1 and 24 h show increased
VEGF and AT1R staining. Black arrows indicate areas of
infiltrating cells positive for VEGF or AT1R.
Figure S3. Temporal changes in proangionenic growth
factor concentration in liver lysates and serum following
OXi4503 treatment. Tissues were collected at indicated
times following OXi4503 treatment. Growth factor con-
centration was determined in lysates by capture ELISA
assays using commercially available kits (R&D Duo Kits)
, control tumor bearing mice; , Oxi4503 treated tumor
bearing mice; naive mice (no tumor induction) The
data are mean values SEM (n = 10) First row, temporal
changes in growth factors in liver lysates of treated ani-
mals were not significantly different from controls. Liver
lysates from tumor bearing animals express significantly
higher levels of all 3 growth factors compared to naive
mice, HGF *P < 0.005, TGF-b *P < 0.01 and VEGF,
*P < 0.05. Second row, temporal changes in growth fac-
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tors in serum. HGF treated at 5 days *P < 0.001 com-
pared to untreated control. TGF-b treated at 24 h
*P < 0.002 and *P < 0.0009 at 5 days following OXi4503
treatment respectively compared to untreated controls.
Sera from tumor bearing animals express significantly
higher levels of TGF-b than sera from naive animals,
*P < 0.03.
Figure S4. Changes in EMT markers following OXi4503
treatment of tumor metastases. Mice with liver metastases
were treated with a single IP dose of OXi4503 (100 mg/
kg) at 16 days post tumor induction. Tissues were col-
lected at 1, 24 h and 5 days following OXi4503 treatment.
Formalin fixed control and treated tumor sections in col-
umns 1–4 were stained with antibodies to E-cadherin,
b-catenin, vimentin and ZEB1 respectively. Positive
expression is detected by the brown staining. Red arrows
indicate area of the viable tumor rim at 1 and 24 h after
treatment. Black bar = 250 lm. L, liver; T, tumor; N,
treatment induced necrosis..
Table S1. List of antibodies and conditions used.
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